Cladribine - Johnson and Johnson/Merck Serono
Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Mavenclad; Movectro; Mylinax; PRMavenclad; RWJ-26251Latest Information Update: 02 Sep 2024
At a glance
- Originator Scripps Clinic
- Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
- Class Antineoplastics; Antipsoriatics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Skin disorder therapies; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
- Phase III Myasthenia gravis
- No development reported Psoriasis; Transplant rejection
Most Recent Events
- 25 Jun 2024 Phase-III clinical trials in Myasthenia gravis (Treatment-experienced) in South Korea, South Korea, USA (PO) (NCT06463587)
- 25 Jun 2024 Phase-III clinical trials in Myasthenia gravis (Treatment-experienced) in Japan (PO) (NCT06463587)
- 18 Jun 2024 Merck Healthcare KGaA plans to initiate a phase III trial for Myasthenia Gravis in the US and Germany (PO) (NCT06463587)